The University of Chicago Header Logo

Connection

Mark Talamonti to Pancreatic Neoplasms

Back to Details
This is a "connection" page, showing publications Mark Talamonti has written about Pancreatic Neoplasms.
Mark Talamonti
Connection Strength
10.554
Pancreatic Neoplasms
  1. Modern Treatment Strategies for Borderline Resectable Pancreatic Cancer. Cancer Treat Res. 2024; 192:67-88.
    View in: PubMed
    Score: 0.605
  2. Endovascular management of portal vein obstruction in hepatobiliary cancer patients. J Surg Oncol. 2022 Mar; 125(3):392-398.
    View in: PubMed
    Score: 0.519
  3. Postoperative venous thromboembolism and mortality in patients with pancreatic surgery. J Surg Oncol. 2019 Sep; 120(3):494-500.
    View in: PubMed
    Score: 0.442
  4. Pancreatic cancer thromboembolic outcomes: rate of thrombosis after adenocarcinoma and non-adenocarcinoma pancreatic cancer surgery. Int Angiol. 2019 Jun; 38(3):194-200.
    View in: PubMed
    Score: 0.439
  5. Management Controversies and Treatment Strategies for Borderline Resectable Pancreatic Cancer. Cancer Treat Res. 2016; 168:59-75.
    View in: PubMed
    Score: 0.347
  6. Screening Strategies for Pancreatic Cancer in High-Risk Patients: Opportunities to Make a Real Impact But Many Questions and Challenges Still Ahead. JAMA Surg. 2015 Jun; 150(6):518-9.
    View in: PubMed
    Score: 0.334
  7. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2013 Oct; 154(4):785-91; discussion 791-3.
    View in: PubMed
    Score: 0.297
  8. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011 Jun 01; 80(2):476-82.
    View in: PubMed
    Score: 0.253
  9. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection. J Surg Oncol. 2010 Oct 01; 102(5):539-42.
    View in: PubMed
    Score: 0.241
  10. Quality improvement for pancreatic cancer care: is regionalization a feasible and effective mechanism? Surg Oncol Clin N Am. 2010 Apr; 19(2):371-90.
    View in: PubMed
    Score: 0.233
  11. Neoadjuvant therapy for pancreatic cancer: a current review. J Surg Oncol. 2010 Mar 15; 101(4):315-20.
    View in: PubMed
    Score: 0.232
  12. Quality of pancreatic cancer care at Veterans Administration compared with non-Veterans Administration hospitals. Am J Surg. 2007 Nov; 194(5):588-93.
    View in: PubMed
    Score: 0.197
  13. Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience. Surgery. 2007 Oct; 142(4):529-34; discussion 534-7.
    View in: PubMed
    Score: 0.196
  14. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer. 2007 Sep 15; 110(6):1227-34.
    View in: PubMed
    Score: 0.196
  15. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007 Aug 15; 110(4):738-44.
    View in: PubMed
    Score: 0.194
  16. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg. 2007 Oct; 205(4):558-63.
    View in: PubMed
    Score: 0.194
  17. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007 Aug; 246(2):173-80.
    View in: PubMed
    Score: 0.194
  18. Guidelines for the surgical management of pancreatic adenocarcinoma. Semin Oncol. 2007 Aug; 34(4):311-20.
    View in: PubMed
    Score: 0.194
  19. Borderline resectable pancreatic cancer: a new classification for an old challenge. Ann Surg Oncol. 2006 Aug; 13(8):1019-20.
    View in: PubMed
    Score: 0.180
  20. Incidence of benign inflammatory disease in patients undergoing Whipple procedure for clinically suspected carcinoma: a single-institution experience. Am J Surg. 2006 Mar; 191(3):437-41.
    View in: PubMed
    Score: 0.176
  21. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006 Feb; 13(2):150-8.
    View in: PubMed
    Score: 0.174
  22. Surgical management of pancreatic cancer. Semin Radiat Oncol. 2005 Oct; 15(4):218-25.
    View in: PubMed
    Score: 0.171
  23. Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlations. Sci Rep. 2024 07 08; 14(1):15744.
    View in: PubMed
    Score: 0.157
  24. Does minimally invasive surgery have a different impact on recurrence and overall survival in patients with pancreatic head versus body/tail cancer? J Surg Oncol. 2023 Jul; 128(1):23-32.
    View in: PubMed
    Score: 0.143
  25. Staging and surgical management of pancreatic and biliary cancer and inflammation. Radiol Clin North Am. 2002 Dec; 40(6):1397-410, viii.
    View in: PubMed
    Score: 0.140
  26. Extended postoperative thromboprophylaxis after pancreatic resection for pancreatic cancer is associated with decreased risk of venous thromboembolism in the minimally invasive approach. J Surg Oncol. 2023 Mar; 127(3):413-425.
    View in: PubMed
    Score: 0.140
  27. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol. 2000 Oct 01; 18(19):3384-9.
    View in: PubMed
    Score: 0.121
  28. Variation in Hospital Utilization of Minimally Invasive Distal Pancreatectomy for Localized Pancreatic Neoplasms. J Gastrointest Surg. 2020 12; 24(12):2780-2788.
    View in: PubMed
    Score: 0.114
  29. The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
    View in: PubMed
    Score: 0.104
  30. Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? Surgery. 2018 05; 163(5):1047-1052.
    View in: PubMed
    Score: 0.100
  31. The extent of vascular resection is associated with perioperative outcome in patients undergoing pancreaticoduodenectomy. HPB (Oxford). 2018 02; 20(2):140-146.
    View in: PubMed
    Score: 0.099
  32. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
    View in: PubMed
    Score: 0.098
  33. Laparoscopic Distal Pancreatectomy for Cancer Provides Oncologic Outcomes and Overall Survival Identical to Open Distal Pancreatectomy. J Gastrointest Surg. 2017 Oct; 21(10):1620-1625.
    View in: PubMed
    Score: 0.097
  34. Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience. Ann Surg Oncol. 2017 Sep; 24(9):2770-2776.
    View in: PubMed
    Score: 0.096
  35. Laparoscopic pancreaticoduodenectomy for adenocarcinoma provides short-term oncologic outcomes and long-term overall survival rates similar to those for open pancreaticoduodenectomy. Am J Surg. 2017 Mar; 213(3):512-515.
    View in: PubMed
    Score: 0.093
  36. Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. Am J Surg. 2017 Mar; 213(3):521-525.
    View in: PubMed
    Score: 0.093
  37. A Multi-institutional Comparison of Perioperative Outcomes of Robotic and Open Pancreaticoduodenectomy. Ann Surg. 2016 Oct; 264(4):640-9.
    View in: PubMed
    Score: 0.092
  38. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma. Surgery. 2016 12; 160(6):1466-1476.
    View in: PubMed
    Score: 0.091
  39. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137.
    View in: PubMed
    Score: 0.091
  40. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Surgery. 2016 09; 160(3):714-24.
    View in: PubMed
    Score: 0.090
  41. A Graded Evaluation of Outcomes Following Pancreaticoduodenectomy with Major Vascular Resection in Pancreatic Cancer. J Gastrointest Surg. 2016 Feb; 20(2):284-92.
    View in: PubMed
    Score: 0.087
  42. The Learning Curve Is Surmountable: In Reply to Fong and colleagues. J Am Coll Surg. 2016 Feb; 222(2):210-1.
    View in: PubMed
    Score: 0.087
  43. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015 Oct; 47(10):1168-78.
    View in: PubMed
    Score: 0.085
  44. Early National Experience with Laparoscopic Pancreaticoduodenectomy for Ductal Adenocarcinoma: A Comparison of Laparoscopic Pancreaticoduodenectomy and Open Pancreaticoduodenectomy from the National Cancer Data Base. J Am Coll Surg. 2015 Jul; 221(1):175-84.
    View in: PubMed
    Score: 0.083
  45. Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med. 2015 Jun; 4(6):853-63.
    View in: PubMed
    Score: 0.082
  46. The laparoscopic approach to distal pancreatectomy for ductal adenocarcinoma results in shorter lengths of stay without compromising oncologic outcomes. Am J Surg. 2015 Mar; 209(3):557-63.
    View in: PubMed
    Score: 0.081
  47. Cystic neoplasms of the pancreas. J Am Coll Surg. 1994 Dec; 179(6):747-57.
    View in: PubMed
    Score: 0.081
  48. CA 19-9 nonproduction is associated with poor survival after resection of pancreatic adenocarcinoma. Am J Clin Oncol. 2014 Dec; 37(6):550-4.
    View in: PubMed
    Score: 0.081
  49. Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2014 Dec; 156(6):1504-10; discussion 1510-1.
    View in: PubMed
    Score: 0.080
  50. Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors. J Gastrointest Surg. 2015 Jan; 19(1):117-23; discussion 123.
    View in: PubMed
    Score: 0.079
  51. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014 Aug; 260(2):372-7.
    View in: PubMed
    Score: 0.079
  52. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg. 2013 Jan; 17(1):94-100; discussion p. 100-1.
    View in: PubMed
    Score: 0.070
  53. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut. 2012 Oct; 61(10):1454-64.
    View in: PubMed
    Score: 0.066
  54. Adding days spent in readmission to the initial postoperative length of stay limits the perceived benefit of laparoscopic distal pancreatectomy when compared with open distal pancreatectomy. Am J Surg. 2011 Mar; 201(3):295-9; discussion 299-300.
    View in: PubMed
    Score: 0.062
  55. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 2010 Jul 13; 7(7):e1000307.
    View in: PubMed
    Score: 0.059
  56. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010 Jun 01; 101(7):587-92.
    View in: PubMed
    Score: 0.059
  57. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer. 2010 Apr 01; 116(7):1674-80.
    View in: PubMed
    Score: 0.058
  58. Mucinous nonneoplastic cyst of the pancreas: apomucin phenotype distinguishes this entity from intraductal papillary mucinous neoplasm. Hum Pathol. 2010 Apr; 41(4):513-21.
    View in: PubMed
    Score: 0.057
  59. A prospective single institution comparison of peri-operative outcomes for laparoscopic and open distal pancreatectomy. Surgery. 2009 Oct; 146(4):635-43; discussion 643-5.
    View in: PubMed
    Score: 0.056
  60. Assessment of pancreatic cancer care in the United States based on formally developed quality indicators. J Natl Cancer Inst. 2009 Jun 16; 101(12):848-59.
    View in: PubMed
    Score: 0.055
  61. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009 Jul; 16(7):1727-33.
    View in: PubMed
    Score: 0.055
  62. Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol. 2009 Feb 01; 99(2):119-22.
    View in: PubMed
    Score: 0.054
  63. Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg. 2008 Dec; 12(12):2078-86.
    View in: PubMed
    Score: 0.053
  64. Effect of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer. Arch Surg. 2008 Jul; 143(7):671-8; discussion 678.
    View in: PubMed
    Score: 0.052
  65. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg. 2008 Oct; 207(4):510-9.
    View in: PubMed
    Score: 0.052
  66. Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1beta. Mod Pathol. 2008 Sep; 21(9):1075-83.
    View in: PubMed
    Score: 0.051
  67. Sociodemographic and tumor characteristics associated with pancreatic cancer surgery in the United States. J Surg Oncol. 2008 Jun 01; 97(7):578-82.
    View in: PubMed
    Score: 0.051
  68. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008 Mar; 247(3):490-500.
    View in: PubMed
    Score: 0.050
  69. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20; 26(6):942-7.
    View in: PubMed
    Score: 0.050
  70. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2007 Nov; 5(10):998-1033.
    View in: PubMed
    Score: 0.049
  71. Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells. Anticancer Drugs. 2007 Jun; 18(5):535-41.
    View in: PubMed
    Score: 0.048
  72. Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res. 2007 Apr; 138(2):163-9.
    View in: PubMed
    Score: 0.047
  73. On the mechanisms of 12-O-tetradecanoylphorbol-13-acetate-induced growth arrest in pancreatic cancer cells. Pancreas. 2006 Aug; 33(2):148-55.
    View in: PubMed
    Score: 0.045
  74. A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest. Biochem Biophys Res Commun. 2006 Feb 24; 340(4):1224-8.
    View in: PubMed
    Score: 0.043
  75. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun. 2005 Sep 30; 335(3):949-56.
    View in: PubMed
    Score: 0.043
  76. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005 Sep; 3(5):598-626.
    View in: PubMed
    Score: 0.042
  77. Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. Mol Cancer. 2005 Aug 05; 4:27.
    View in: PubMed
    Score: 0.042
  78. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res. 2005 Jul 15; 65(14):6011-6.
    View in: PubMed
    Score: 0.042
  79. A novel anti-pancreatic cancer agent, LY293111. Anticancer Drugs. 2005 Jun; 16(5):467-73.
    View in: PubMed
    Score: 0.042
  80. LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia. 2005 Apr; 7(4):417-25.
    View in: PubMed
    Score: 0.041
  81. Pancreatic cancer stimulates pancreatic stellate cell proliferation and TIMP-1 production through the MAP kinase pathway. Biochem Biophys Res Commun. 2004 Oct 29; 323(4):1241-5.
    View in: PubMed
    Score: 0.040
  82. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001 Oct; 130(4):677-82; discussion 682-5.
    View in: PubMed
    Score: 0.032
  83. Risk factors for complications in patients undergoing pancreaticoduodenectomy: A NSQIP analysis with propensity score matching. J Surg Oncol. 2020 Aug; 122(2):183-194.
    View in: PubMed
    Score: 0.029
  84. zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells. Int J Cancer. 1999 Oct 29; 83(3):349-58.
    View in: PubMed
    Score: 0.028
  85. Tight junction protein ZO-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma. Int J Cancer. 1999 Jul 02; 82(1):137-44.
    View in: PubMed
    Score: 0.028
  86. Cystic neoplasms of the pancreas. A clinicopathologic study, including DNA flow cytometry. Arch Surg. 1995 Oct; 130(10):1048-54.
    View in: PubMed
    Score: 0.021
  87. Atypical acinar cell foci in human pancreas. Morphological and morphometric analysis. Int J Pancreatol. 1997 Oct; 22(2):127-30.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.